Flibanserin Completed Phase 3 Trials for Sexual Dysfunctions, Psychological Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00277914Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women
NCT00360555Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
NCT0036052924-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder
NCT003602436-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA
NCT00491829Flibanserin Versus Placebo in Premenopausal Women With HSDD
NCT00601367Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
NCT00996372Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
NCT00996164Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder